Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Oncol Lett. 2019 Jun;17(6):4891-4900. doi: 10.3892/ol.2019.10153. Epub 2019 Mar 15.

2.

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.

Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J.

J Thorac Oncol. 2019 Apr;14(4):606-616. doi: 10.1016/j.jtho.2018.12.013. Epub 2018 Dec 31.

3.

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J.

Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333.

4.

ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Med Oncol. 2018 Jun 15;35(7):106. doi: 10.1007/s12032-018-1169-5.

PMID:
29905882
5.

Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.

Christopoulos P, Schneider MA, Bozorgmehr F, Kuon J, Engel-Riedel W, Kollmeier J, Baum V, Muley T, Schnabel PA, Bischoff H, Grohé C, Serke M, Thomas M, Fisch P, Meister M.

Lung Cancer. 2018 May;119:48-55. doi: 10.1016/j.lungcan.2018.03.002. Epub 2018 Mar 6.

PMID:
29656752
6.

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).

Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J.

Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3.

7.

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M.

Lung Cancer (Auckl). 2017 Nov 6;8:217-229. doi: 10.2147/LCTT.S142972. eCollection 2017.

8.

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup.

Garrido P, Chouaki N, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Soldatenkova V, Novello S.

ESMO Open. 2017 Mar 9;2(1):e000141. doi: 10.1136/esmoopen-2016-000141. eCollection 2017. No abstract available.

9.

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel PA, Serke M, Thomas M.

Ann Oncol. 2017 Aug 1;28(8):1898-1902. doi: 10.1093/annonc/mdx268.

PMID:
28535181
10.

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.

Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J.

J Thorac Oncol. 2016 Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016.

11.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators.

J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.

12.

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.

Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, Schumann C, Serke M, Zaun S, Dietel M, Thomas M.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61. doi: 10.1158/1055-9965.EPI-14-1149. Epub 2015 Jun 12.

13.

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J.

Oncotarget. 2015 Apr 30;6(12):10577-85.

14.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M; ABC-Lung Cancer Group.

Eur Respir J. 2015 Jul;46(1):219-29. doi: 10.1183/09031936.00229014. Epub 2015 Mar 18.

15.

Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).

Garrido P, Engel-Riedel W, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Ameryckx S, Soldatenkova V, Chouaki N, Novello S.

Lung Cancer. 2015 May;88(2):160-6. doi: 10.1016/j.lungcan.2015.02.014. Epub 2015 Feb 23.

16.

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.

Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R.

Clin Cancer Res. 2015 Feb 15;21(4):907-15. doi: 10.1158/1078-0432.CCR-14-0450. Epub 2014 Dec 9.

17.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J.

Oncotarget. 2015 Jan 20;6(2):1315-26.

18.

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC).

J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380.

19.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, Serke M, Favaretto A, Szczesna A, Cobo M, Ciuffreda L, Jassem J, Nicolini M, Ramlau R, Amoroso D, Melotti B, Almodovar T, Riggi M, Caux NR, Vaissière N, Tan EH.

Clin Lung Cancer. 2014 Jul;15(4):258-65. doi: 10.1016/j.cllc.2014.04.007. Epub 2014 May 15.

PMID:
24954228
20.

Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.

Hörsch D, Schmid KW, Anlauf M, Darwiche K, Denecke T, Baum RP, Spitzweg C, Grohé C, Presselt N, Stremmel C, Heigener DF, Serke M, Kegel T, Pavel M, Waller CF, Deppermann KM, Arnold R, Huber RM, Weber MM, Hoffmann H.

Oncol Res Treat. 2014;37(5):266-76. doi: 10.1159/000362430. Epub 2014 Apr 14. Review.

PMID:
24853787
21.

[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].

Wiewrodt R, Serke M, Grohé C, Brückl W.

Pneumologie. 2013 Sep;67(9):494-501. doi: 10.1055/s-0033-1344337. Epub 2013 Sep 4. Review. German.

22.

[Gender-specific difference in lung cancer].

Serke M, Stanzel F, Westhoff M.

Pneumologie. 2013 May;67(5):270-9. doi: 10.1055/s-0033-1343149. Epub 2013 May 15. German.

23.

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators.

Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.

PMID:
23161898
24.

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.

Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner R.

Mod Pathol. 2012 Nov;25(11):1473-80. doi: 10.1038/modpathol.2012.102. Epub 2012 Jun 8.

25.

[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version].

Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübbe AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heussel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingräber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H; German Respiratory Society; German Cancer Society.

Pneumologie. 2011 Aug;65(8):e51-75. doi: 10.1055/s-0030-1256562. Epub 2011 Aug 9. German. No abstract available.

26.

Postmenopausale Frauen: Lungenkrebsrisiko unter Hormontherapie?

Serke M.

MMW Fortschr Med. 2011 Jun;153(23):30. doi: 10.1007/BF03368521. German. No abstract available.

PMID:
27369418
27.

Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society.

Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübbe AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heussel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingräber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H; German Respiratory Society; German Cancer Society.

Pneumologie. 2011 Jan;65(1):39-59. doi: 10.1055/s-0030-1255961. Epub 2010 Dec 14. No abstract available.

28.

[Current developments and perspectives in targeted therapies].

Dickgreber N, Huber RM, Reck M, Reinmuth N, Schütte W, Serke M, Wolf J.

Onkologie. 2010;33 Suppl 5:2-11. doi: 10.1159/000313971. Epub 2010 May 14. Review. German.

29.

[Prevention, diagnosis, therapy, and follow-up of lung cancer].

Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübbe AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heussel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingräber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H; Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin und die Deutsche Krebsgesellschaft.

Pneumologie. 2010 Mar;64 Suppl 2:e1-164. doi: 10.1055/s-0029-1243837. Epub 2010 Mar 9. German. No abstract available.

PMID:
20217630
30.

Adjuvant therapy in early-stage non-small cell lung cancer.

Serke M.

Front Radiat Ther Oncol. 2010;42:135-144. doi: 10.1159/000262468. Epub 2009 Nov 24. Review.

PMID:
19955799
31.

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.

Respir Med. 2010 Jan;104(1):142-8. doi: 10.1016/j.rmed.2009.07.019. Epub 2009 Oct 8.

32.

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M.

J Occup Med Toxicol. 2008 Dec 18;3:34. doi: 10.1186/1745-6673-3-34.

33.

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E.

Br J Cancer. 2008 Dec 16;99(12):2006-12. doi: 10.1038/sj.bjc.6604808.

34.

A 62-year-old woman with bilateral pleural effusions and pulmonary infiltrates caused by extramedullary hematopoiesis.

Schwarz C, Bittner R, Kirsch A, Loddenkemper C, Mairinger T, Schonfeld N, Serke M, Loddenkemper R.

Respiration. 2009;78(1):110-3. doi: 10.1159/000150913. Epub 2008 Aug 4.

PMID:
18679016
35.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

36.

Computed tomography for diagnosis and grading of dust-induced occupational lung disease.

Blum T, Kollmeier J, Ott S, Serke M, Schönfeld N, Bauer T.

Curr Opin Pulm Med. 2008 Mar;14(2):135-40. doi: 10.1097/MCP.0b013e3282f5248e. Review.

PMID:
18303423
37.

[Modern endoscopic procedures for diseases of the respiratory tract].

Schönfeld N, Temme T, Schwarz C, Serke M, Ott S.

Dtsch Med Wochenschr. 2007 Dec;132(49):2633-6. Review. German.

PMID:
18050029
38.

[Multimodal therapy of small cell and non-small cell lung carcinoma].

Serke M, Kollmeier J.

Dtsch Med Wochenschr. 2007 Jun 1;132(22):1221-4. Review. German.

PMID:
17520508
39.

[Diagnosis and staging of lung cancer].

Serke M, Schönfeld N.

Dtsch Med Wochenschr. 2007 May 25;132(21):1165-9. Review. German.

PMID:
17506012
40.

[Lung cancer: targeted therapy].

Serke M.

Pneumologie. 2007 Mar;61(3):162-70. German.

PMID:
17342577
41.

[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].

Deppermann KM, Huber RM, Laack E, Reck M, Serke M, von Pawel J.

Onkologie. 2006 Sep;29 Suppl 2:15-9. Epub 2006 Sep 6. Review. German. No abstract available.

PMID:
16974123
42.

[Pharmacologic treatment of bronchial cancer. Part 1: Standards].

Serke M.

Pneumologie. 2006 Aug;60(8):493-508. German.

PMID:
16933193
43.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M.

J Clin Oncol. 2005 Nov 20;23(33):8389-95.

PMID:
16293869
44.

[Therapeutic options in malignant pleural mesothelioma].

Serke M, Loddenkemper R.

Pneumologie. 2005 May;59(5):337-48. Review. German.

PMID:
15902599
45.

Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer.

Schwarz C, Lübbert H, Rahn W, Schönfeld N, Serke M, Loddenkemper R.

Eur Respir J. 2004 Nov;24(5):728-30.

46.

[Adjuvant chemotherapy in non-small-cell lung cancer: proven survival benefit].

Serke M.

Pneumologie. 2004 Jun;58(6):393-4. German. No abstract available.

PMID:
15216430
47.

Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.

Serke M, Schoenfeld N, Loddenkemper R.

Anticancer Res. 2004 Mar-Apr;24(2C):1211-6.

48.

[Recommendations on the therapy of bronchial carcinoma].

Thomas M, Baumann M, Deppermann M, Freitag L, Gatzemeier U, Huber R, Passlick B, Serke M, Ukena D.

Pneumologie. 2002 Feb;56(2):113-31. Review. German. No abstract available.

PMID:
11842350
49.

[Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy].

Serke M, Allica E, Wolf M, Schönfeld N, Kaiser D, Loddenkemper R.

Kongressbd Dtsch Ges Chir Kongr. 2001;118:606-10. German.

PMID:
11824325
50.

[Multimodality therapy concept in stage I-IIIA small cell bronchial carcinoma. Case follow-up over 15 years].

Allica E, Serke M, Loddenkemper R, Kaiser D.

Kongressbd Dtsch Ges Chir Kongr. 2001;118:596-600. German.

PMID:
11824323

Supplemental Content

Support Center